Philip Kong joins the 2020 Blavatnik Fellowship cohort as an entrepreneur and a scientist. Philip is an expert in immunology and nanotechnology by training, and he developed a novel nanotechnology platform specifically designed to deliver active pharmaceutical drugs to target cells in an optimal sequence. As the chief inventor of the technology, he became the co-founder and the Chief Scientific Officer of Statera Therapeutics, a platform biotech spun out of Yale University focusing on treatment of autoimmune diseases, allergies, and cancer. In Statera Therapeutics, Philip oversees the pre-clinical development of nanotechnology and expands collaboration with leading academic faculties and CROs. Under Philip and the Statera management team, Statera has won several awards, including first place in NYU vs. Yale pitchoff competition and Connecticut Innovations Biopipeline program. Statera also secured significant financial support from the family office. In addition to entrepreneurship, Philip is a leading authority in immunology, publishing several papers in distinguished journals, such as Science, Cell Host & Microbes, and Journal of Clinical Investigation. His scientific excellence is also recognized by awards such as Fulbright scholarship, Amgen scholarship, and Intel STS. Philip also brings years of buy-side experience in a biotech hedge fund, consulting on publicly traded biotech companies. He received his B.S. in biology from California Institute of Technology, and PhD in immunobiology from Yale University